Cold endoscopic mucosal resection (EMR) demonstrates lower rates of delayed bleeding and perforation but a higher risk for recurrent or residual neoplasia than hot EMR in colorectal polyp treatment.

CARDIFF, UK / ACCESS Newswire / February 12, 2025 /Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage ...

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis Underscores unmet need for a ...

Ms Lauren V O’Connell was recently announced by the Royal College of Surgeons in Ireland (RCSI) as the recipient of the 2025 ...

Emily King of Mobile, Alabama, was diagnosed with colon cancer five years ago at the age of 27. She had experienced some diarrhea, abdominal pain and anemia, but having cancer had never entered ...

CARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatmen ...

A phase Ib study of immunotherapy with ex-vivo pre-activated and expanded CBNK cells in combination with cetuximab, in patients with colorectal cancer (CRC) with minimal residual disease (MRD): Final ...

The modified intention-to-treat analysis included 1,550 colorectal cancer patients who had undergone resection and had completed standard adjuvant therapy (at least 3 months of chemotherapy).

The U.K. biopharmaceutical company said data from a Phase 2 study of eRapa, a treatment for familial adenomatous polyposis, showed the drug to be safe and well-tolerated among users. The treatment ...

Investigators included adults with Dukes' C or high-risk Dukes' B colon cancer or Dukes' B or C rectal cancer who completed resection and at least three months of chemotherapy. Patients were ...

DNA testing may inform treatment decisions and predict outcomes of adjuvant chemotherapy in patients with stage II-III colorectal cancer.

Patients with BRAF V600E-mutant metastatic colorectal cancer experienced poor clinical outcomes with systemic therapy, ...